The ENRICH trial, published in The Lancet in October 2025, delivers the first large randomized test of a chemotherapy‑free front‑line strategy for this population. It compares the oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib combined with the anti‑CD20 antibody rituximab against standard immunochemotherapy.
